ALK-Abello A/S - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 49

ALK-Abello A/S – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “ALK-Abello A/S - Product Pipeline Review - 2012” provides data on the ALK-Abello A/S’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ALK-Abello A/S’s corporate website, SEC filings, investor presentations and featured press releases, both from ALK-Abello A/S and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ALK-Abello A/S - Brief ALK-Abello A/S overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ALK-Abello A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ALK-Abello A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ALK-Abello A/S’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ALK-Abello A/S’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ALK-Abello A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ALK-Abello A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ALK-Abello A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ALK-Abello A/S and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of ALK-Abello A/S; ALK-Abello A/S - Key Therapeutics; ALK-Abello A/S - Pipeline Overview and Promising Molecules; ALK-Abello A/S - News; ALK-Abello A/S - Latest Updates; ALK-Abello A/S - Pipeline; ALK-Abello A/S - Discontinued/Dormant Projects

List of Tables
List of Figures
ALK-Abello A/S Snapshot
ALK-Abello A/S Overview
Key Information
Key Facts
ALK-Abello A/S – Research and Development Overview
Key Therapeutic Areas
ALK-Abello A/S – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
ALK-Abello A/S – Pipeline Products Glance
ALK-Abello A/S – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
ALK-Abello A/S Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
ALK-Abello A/S – Drug Profiles
ALK Birch Pollen Vaccine
Product Description
Mechanism of Action
R&D Progress
ALK Ragweed Vaccine
Product Description
Mechanism of Action
R&D Progress
Grazax
Product Description
Mechanism of Action
R&D Progress
Mitizax
Product Description
Mechanism of Action
R&D Progress
Osiris
Product Description
Mechanism of Action
R&D Progress
ALK-Abello A/S – Pipeline Analysis
ALK-Abello A/S – Pipeline Products by Therapeutic Class
ALK-Abello A/S – Pipeline Products by Route of Administration
ALK-Abello A/S – Recent Pipeline Updates
ALK-Abello A/S - Dormant Projects
ALK-Abello A/S – Company Statement
ALK-Abello A/S – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
ALK-Abello A/S - Key Manufacturing Facilities
Financial Deals Landscape
ALK-Abello A/S, Deals Summary
ALK-Abello A/S, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
DBV Technologies Secures $25.5 Million In Series C Venture Financing Round
DBV Technologies Secures $7.75 Million In Series B Financing
Partnerships
AllerQuest Enters Into Agreement With ALK-Abello
Catalent Pharma Enters Into An Agreement With ALK-Abello
ALK-Abello Enters Into An Agreement With Menarini
ALK-Abello Enters Into Joint Venture With Copenhagen University And NOVI Innovation
Licensing Agreements
ALK-Abello Enters Into Licensing Agreement With Torii Pharma For Alutard And MITIZAX
Alk-Abello Enters Into A Strategic Alliance Schering-Plough
PBM Products Enters Into Licensing Agreement With Arla Foods And ALK-Abello
Acquisition
Fornix BioSciences Completes Sale Of Artu Biologicals To ALK-Abello
ALK-Abello Acquires ThemoCARE
ALK-Abello Acquires ALK-Scherax From Schering
ALK-Abello Acquires Allerbio
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
ALK-Abello A/S, Key Information
ALK-Abello A/S, Key Facts
ALK-Abello A/S – Pipeline by Indication, 2012
ALK-Abello A/S – Pipeline by Stage of Development, 2012
ALK-Abello A/S – Monotherapy Products in Pipeline, 2012
ALK-Abello A/S – Filed, 2012
ALK-Abello A/S – Phase III, 2012
ALK-Abello A/S – Phase II, 2012
ALK-Abello A/S – Phase I, 2012
ALK-Abello A/S – Pipeline By Therapeutic Class, 2012
ALK-Abello A/S – Pipeline By Route of Administration, 2012
ALK-Abello A/S – Recent Pipeline Updates, 2012
ALK-Abello A/S - Dormant Developmental Projects,2012
ALK-Abello A/S, Other Locations
ALK-Abello A/S, Subsidiaries
ALK-Abello A/S, Key Manufacturing Facilities
ALK-Abello A/S, Deals Summary
DBV Technologies Secures $25.5 Million In Series C Venture Financing Round
DBV Technologies Secures $7.75 Million In Series B Financing
AllerQuest Enters Into Agreement With ALK-Abello
Catalent Pharma Enters Into An Agreement With ALK-Abello
ALK-Abello Enters Into An Agreement With Menarini
ALK-Abello Enters Into Joint Venture With Copenhagen University And NOVI Innovation
ALK-Abello Enters Into Licensing Agreement With Torii Pharma For Alutard And MITIZAX
Alk-Abello Enters Into A Strategic Alliance Schering-Plough
PBM Products Enters Into Licensing Agreement With Arla Foods And ALK-Abello
Fornix BioSciences Completes Sale Of Artu Biologicals To ALK-Abello
ALK-Abello Acquires ThemoCARE
ALK-Abello Acquires ALK-Scherax From Schering
ALK-Abello Acquires Allerbio

List of Figures
ALK-Abello A/S – Pipeline by Indication, 2012
ALK-Abello A/S – Pipeline by Stage of Development, 2012
ALK-Abello A/S – Monotherapy Products in Pipeline, 2012
ALK-Abello A/S – Pipeline By Therapeutic Class, 2012
ALK-Abello A/S – Pipeline By Route of Administration, 2012

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Scientific Games Corporation - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• Ixia - Company Analysis
• Accenture - Profile - US